Arch Therapeutics, Inc. (ARTHQ)

Arch Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Net Income	-12.26	-6.98	-5.28	-6.24	-4.69	-4.55
Depreciation & Amortization	0	0	0	0	0.01	0.01
Other Amortization	2.68	2.31	0.3	-	-	-
Stock-Based Compensation	0.07	0.25	0.5	0.5	0.9	1.23
Other Operating Activities	3.96	-1.16	-0.75	-0.11	-0.62	-1.82
Change in Inventory	0.06	0.05	-0.57	-0.31	-0.68	-0.35
Change in Accounts Payable	0.45	0.98	0.85	0.07	-0.19	0.37
Change in Other Net Operating Assets	1.33	1.18	0.49	0.13	0.23	-0.16
Operating Cash Flow	-3.7	-3.37	-4.46	-5.96	-5.04	-5.27
Capital Expenditures	-0	-0	-	-0	-0	-
Investing Cash Flow	-0	-0	-	-0	-0	-
Long-Term Debt Issued	-	1	3.04	1.05	0.73	-
Total Debt Issued	1.78	1	3.04	1.05	0.73	-
Short-Term Debt Repaid	-	-0.35	-0.11	-	-	-
Total Debt Repaid	-0.35	-0.35	-0.11	-	-	-
Net Debt Issued (Repaid)	1.44	0.64	2.94	1.05	0.73	-
Issuance of Common Stock	2.21	2.21	-	6.22	3.1	1.15
Other Financing Activities	-	-	-	-	-	1.63
Financing Cash Flow	3.65	2.85	2.94	7.27	3.83	2.78
Net Cash Flow	-0.06	-0.52	-1.52	1.31	-1.22	-2.49
Free Cash Flow	-3.71	-3.38	-4.46	-5.96	-5.05	-5.27
Free Cash Flow Margin	-2501.07%	-4461.91%	-28469.68%	-51551.26%	-	-
Free Cash Flow Per Share	-0.67	-1.10	-3.71	-5.42	-5.37	-6.33
Levered Free Cash Flow	-3.72	-1.34	-2.52	-2.63	-3	-2.88
Unlevered Free Cash Flow	-1.69	-1.71	-2.47	-2.53	-2.98	-2.88
Change in Net Working Capital	-1.19	-1.19	-0.59	-0.96	0.64	0.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.